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Summary 
 
According to the 2016 World Health Organization Classification of Tumors of the Central 
Nervous System (2016 CNS WHO), IDH-mutant astrocytic gliomas are comprised of WHO 
grade II diffuse astrocytoma, IDH-mutant (AIIIDHmut), WHO grade III anaplastic astrocytoma, 
IDH-mutant (AAIIIIDHmut), and WHO grade IV glioblastoma, IDH-mutant (GBMIDHmut). Notably, 
IDH gene status has been made the major criterion for classification while the manner of 
grading has remained unchanged: it is based on histological criteria that arose from studies 
which antedated knowledge of the importance of IDH status in diffuse astrocytic tumor 
prognostic assessment. Several studies have now demonstrated that the anticipated 
differences in survival between the newly defined AIIIDHmut and AAIIIIDHmut have lost their 
significance. In contrast, GBMIDHmut still exhibits a significantly worse outcome than its lower 
grade IDH-mutant counterparts. To address the problem of establishing prognostically 
significant grading for IDH-mutant astrocytic gliomas in the IDH era, we undertook a 
comprehensive study that included assessment of histological and genetic approaches to 
prognosis in these tumors. A discovery cohort of 211 IDH-mutant astrocytic gliomas with an 
extended observation was subjected to histological review, image analysis, and DNA 
methylation studies. Tumor group–specific methylation profiles and copy number variation 
profiles (CNV) were established for all gliomas. Algorithms for automated CNV analysis were 
developed. All tumors exhibiting 1p/19q codeletion were excluded from the series. We 
developed algorithms for grading, based on molecular, morphological and clinical data. 
Performance of these algorithms was compared with that of WHO grading. Three 
independent cohorts of 108, 154 and 224 IDH-mutant astrocytic gliomas were used to 
validate this approach. In the discovery cohort several molecular and clinical parameters 
were of prognostic relevance. Most relevant for overall survival (OS) was CDKN2A/B 
homozygous deletion. Other parameters with major influence were necrosis and the total 
number of CNV. Proliferation as assessed by  mitotic count, which is a key parameter in 
2016 CNS WHO grading, was of only minor influence. Employing the parameters most 
relevant for OS in our discovery set, we developed two models for grading these tumors. 
These models performed significantly better than WHO grading in both the discovery and the 
validation sets. Our novel algorithms for grading IDH-mutant astrocytic gliomas overcome the 
challenges caused by introduction of IDH status into the WHO classification of diffuse 
astrocytic tumors. We propose that these revised approaches be used for grading of these 
tumors and incorporated into future WHO criteria. 
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Introduction 
 
Diffuse astrocytic gliomas are the most common brain tumors of adults and their grading has 
therefore been of considerable significance in the management of patients with brain tumors. 
As a result, over the years, these tumors have been graded according to various systems, 
each representing an advance over prior approaches. These have included the Kernohan 
scheme, the St. Anne-Mayo system and, for the past 25 years, primarily the WHO 
classification [8,12,13]. These schemes often resulted in patient groups with significantly 
varying prognoses that received treatments of differing intensity. In recent years the WHO 
classification scheme based on early work from Zulch [38] and regarding astrocytic gliomas 
from Burger [3] has been most widely used [13,14]. 
IDH1 and IDH2 mutations have emerged as early mutations in diffuse astrocytic tumors 
[2,21,35,37], and determination of the IDH status by immunohistochemistry [6] or sequencing 
has now become a standard in the diagnosis of these tumors. The 2016 WHO Classification 
Of Tumors Of The Central Nervous System [14] introduced molecular parameters for the 
categorization of diffuse astrocytomas, notably IDH mutation status [14]. In fact, 
determination of IDH and 1p/19q status is mandatory for diagnosing beyond NOS (not 
otherwise specified) categories. However, applying the new classification parameters results 
in patient groups that are different from those classified prior to the 2016 CNS WHO (e.g. 
according to the 2007 CNS WHO). From the former group of diffuse WHO grade II and III 
astrocytomas, approximately 70% to 80% now are classified as diffuse astrocytoma, IDH-
mutant (AIIIDHmut) and anaplastic astrocytoma, IDH-mutant (AAIIIIDHmut) while 20% to 30% are 
classified as diffuse astrocytoma, IDH-wildtype (AIIIDHwt) and anaplastic astrocytoma, IDH-
wildtype (AAIIIIDHwt). In turn, the shifting of diagnostic groups has prognostic implications. For 
example, multiple studies have demonstrated a close relationship between many 
AIIIDHwt/AAIIIIDHwt to glioblastoma, IDH-wildtype (GBMIDHwt) [4,27,33]. In fact, prior to the 2016 
CNS WHO the prognostic power of grading parameters for diffuse astrocytoma WHO grade 
II (AIINOS) and anaplastic astrocytoma WHO grade III (AAIIINOS) were most likely a result of 
considerable contamination with unrecognized GBMIDHwt [34]. In addition, a series of recent 
studies have highlighted that WHO grading of AIIIDHmut/AAIIIIDHmut has lost its prognostic 
relevance [4,18,20,22,28,33,34]. Given the clinical importance of appropriate grading, the 
potential prognostic changes brought about by the 2016 CNS WHO classification pose a 
major challenge. We therefore sought to establish novel, improved grading criteria for IDH-
mutant astrocytic gliomas.  
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Methods 
 
Study design and participants 
For this multicenter retrospective analysis we collected a discovery series of 211 astrocytic 
tumors. We defined the following criteria for inclusion: 1) all tumors had either an IDH1 or an 
IDH2 mutation; 2) all tumors had a 2016 CNS WHO integrated diagnosis of AIIIDHmut (n=54), 
AAIIIIDHmut (n=90) or GBMIDHmut (n=67), i.e., no tumors had 1p/19q codeletion; 3) sufficient 
formalin-fixed, paraffin-embedded (FFPE) material for morphological and additional 
molecular analyses was available; and 4) the patients had an extended follow up. Tumor 
material was from the archive of the Department of Neuropathology, University of 
Heidelberg, Heidelberg, Germany and from patients enrolled in the NOA04 trial [36]. Use of 
tissue and clinical data was in accordance with local ethical regulations. 
 
Three validation series were compiled. The first validation series from Heidelberg (HD) 
containing 108 tumors differed from the discovery set only in that sufficient material for the 
complete set of analyses performed on the discovery set was not available. The HD 
validation series contained AIIIDHmut (n=32), AAIIIIDHmut (n=29) and GBMIDHmut (n=47). In this 
set diagnosis and grading according to the guidelines of the 2016 CNS WHO was performed 
(AvD). The second validation set from the European Organization for Research and 
Treatment of Cancer (EORTC) contained 154 cases and was compiled from patients of the 
EORTC studies 22033 (64 cases), 26091 (80 cases) and 26981 (10 cases) with Illumina 
450k or 850k/EPIC data being available. All patients in this set also had an IDH mutation and 
none of the tumors harbored a 1p/19q codeletion. The EORTC validation series contained 
AIIIDHmut (n=94), AAIIIIDHmut (n=39) and GBMIDHmut (n=21). In this set diagnosis and grading 
according to the guidelines of the 2016 CNS WHO was performed by reference centers. The 
third validation set from The Cancer Genome Atlas consortium (TCGA) contained 224 cases 
and was retrieved from published data. In this set diagnosis and grading was obtained from 
the source. Methylome data based on Illumina 450k array was available for all of these 
cases. All cases in this set had an IDH mutation as provided by TCGA. and none contained a 
1p/19q codeletion as assessed by copy number profiles which were calculated from the DNA 
methylation data. Clinical data were known to the local investigators (MS, TO, DSt, DSc, 
AvD). Cases from the HD validation set also were reviewed by the same neuropathologist 
(AvD). Clinical data from the HD validation set were known to the lead authors. Clinical data 
from the EORTC validation set were not known to the lead authors. Clinical data for the 
TCGA validation set were open access. The institutional funding of this study did not 
influence study design, inclusion criteria, analyses or interpretation of the data. MS, TO, DSt, 
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DSc and AvD had full access to all raw data except for the EORTC series and had final 
responsibility for the decision to submit for publication.  
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Procedures 
For the discovery set, 4µm-sections were cut from FFPE blocks from all tumors and stained 
with hematoxylin/eosin, and examined by immunohistochemistry with antibodies against 
IDHR132H (clone H09, Dianova, Hamburg, Germany), Ki-67 (clone MIB-1, Dako, 
Waldbronn, Germany) or pHH3 (rabbit polyclonal,BioCare Medical, Pacheco, USA) to 
determine proliferation and CD31 (clone JC70A, Dako, Waldbronn, Germany) to determine 
vascular density.  
All tumor samples were analyzed by Illumina HumanMethylation450 (450k) or 
MethylationEPIC (850k) arrays (Illumina, San Diego, CA, USA) as previously described [32]. 
Methylation data were analyzed by a classifier as previously reported [5]. CNV plots were 
generated using the R/Bioconductor package conumee version 1.6.0. Automated 
assessment of copy-number changes was performed using a proprietary algorithm (Stichel D 
and colleagues, unpublished). This allowed determining CNV load (CNV-L) for each tumor.  
The discovery set was subjected to digital image analysis. Parameters assessed included 
cell count, proliferation activity and microvessel density. The software package Aperio 
ImageScope was employed for proliferation and microvessel density analysis. The software 
packages Ilastik [31] and ImageJ [30] were used for cell count analysis. To receive 
subgroups with distinct OS, conditional trees were created applying the function ctree from 
the R package party on the discovery set and a set of selected input variables. Here, the 
global null hypothesis of independence between any of the input variables and the OS was 
tested. If it couldn't be rejected, the association of any single input variable with the response 
was computed as p-value from a test for the partial null hypothesis of the variable and OS. 
The input variable with the highest association to OS was selected and a binary split in this 
variable was created. This procedure was then repeated to create conditional trees. To 
create Modelpath all parameters received from molecular analyses but CDKN2A/B status 
were excluded. Kaplan-Meier estimators were computed using the function survfit from the R 
package survival. All parameters assessed are listed in table 1. 
Numerical alterations of several genes with established relevance for astrocytic gliomas-- 
comprising CCND1, CCND2, CDK4, CDK6, CDKN2A/B, EGFR, MDM4, MET, MYC, MYCN, 
NF1, NF2, PDGFR2, PPM1D, PTEN, RB1 and SMARCB1-- were evaluated by visual 
assessment of copy number profiles and by employing our proprietary algorithm. Our series 
are based on visual assessment for CDKN2A/B analysis. With the cutoff selected in our 
series, visual and algorithm driven CDKN2A/B evaluation produced the same number of 
cases scored as having a homozygous deletion. The respective genes and cutoff values are 
given in table 2. 
 
Statistical analysis 
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All patient sets were retrospectively compiled. The size of the respective sets was 
determined by availability of data and not by a power calculation. OS times were analyzed by 
the Kaplan-Meier method and compared with a log-rank test. Prediction error plots were 
based on Brier scores. P values less than 0.05 were considered significant. Software R 
version 3.4 and packages survival and party were employed for analysis 
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Results 
 
Series validation and determination of histologic and molecular features associated 
with OS 
On the basis of histological review, all tumors in the discovery set were confirmed to be 
diffuse astrocytic gliomas. Classification according to the 2016 CNS WHO revealed three 
distinct groups, AIIIDHmut, AAIIIIDHmut or GBMIDHmut, with significantly different OS (figure 1a). 
The IDH status was determined by IHC with H09 [6] or by Sanger sequencing. All 
immunonegative samples have been subjected to sequencing. IDH status was also 
confirmed by performing 450k/EPIC analysis and receiving the readout of “methylation group 
astrocytoma IDH mutant” by a recently developed and published classifier tool [5] which 
predicts IDH-mutant astrocytoma with very high specificity and sensitivity. Further, combined 
1p/19q deletion was excluded for every tumor based on analysis of the copy number profile 
(CNP) generated from 450k/EPIC data. Therefore, our series included exclusively AIIIDHmut, 
AAIIIIDHmut or GBMIDHmut, in full agreement with 2016 CNS WHO classification criteria. In the 
discovery set of 211 patients, 135 were still alive at the time of last follow-up. Median follow 
up in these 135 patients was 1772 days (4.9 years); average follow was 2086 days (5.7 
years). 
The morphological parameters of strongest negative prognostic value were vascular 
proliferation (p<0.0005) and necrosis (p<0.00005). Patients aged 55 and older did worse 
(p<0.04) than patients aged below this cutoff confirming the influence of age on OS. Female 
patients fared significantly (p=0.01) better than male patients. Image analysis showed that 
cellularity had a major association with OS. Cell count defined as number of tumor cells per 
square millimeter in the tumor area of highest density emerged as an important parameter for 
prognostic evaluation. Patients with a cell density of 4605/mm2 or more fared worse than 
patients with 4604 or fewer tumor cells/mm2 (p<0.002) Ki-67 immunohistochemistry was 
significantly associated with worse OS (cutoff 14.5%; p<0.006), however, mitotic count 
established by assessing sections treated with pHH3 antibody was not prognostic. (table 1). 
While pHH3 has been established as a reliable marker for assessing mitotic activity, those 
studies have mainly been performed prior to further stratification of diffuse astrocytomas by 
IDH status [7]. In a recent study on IDH-mutant diffuse glioma, pHH3 was found to reliably 
detect mitotic figures but turned out with a weaker association with survival that Ki-67 [10]. 
EPIC- or 450k array data were employed to assess several parameters: this included 
analysis by the brain tumor classifier tool [5] for the confirmation of IDH mutations and 
evaluation of individual copy number status. Copy number plots were evaluated for 
amplifications or homozygous deletions, respectively. In the discovery set regions with such 
alterations contained CCND1, CCND2, CDK4, CDK6, CDKN2A/B, EGFR, MDM4, MET, 
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MYC, MYCN, NF1, NF2, PDGFR2, PPM1D, PTEN, RB1 and SMARCB1 (table 2). Upon 
univariate analysis the strongest association with OS was observed for homozygous 
CDKN2A/B deletion and for MYCN amplification (table 2 and figure 1b). Furthermore, the 
total CNV-load (CNVL) was determined, resulting in a split for a value of 349695798 base 
pairs (rounded 350 Mb). This number refers to the sum of all gains or deletions as 
determined by analysis of the 450k/850k raw data by our proprietary algorithm. 
Patients with higher CNVL fared significantly worse than patients with lower CNVL 
(p<0.0001). However the frequency for all chromosomal gains or losses increased with age 
as demonstrated by summary CNV plots (supplementary figure 1). Further, EPIC/450k array 
methylation data were used for unsupervised clustering of the discovery dataset. This 
analysis yielded two sets with highly significant differences in OS (supplementary figure 2A). 
Likewise, the algorithm underlying our methylation based classifier [5] recognized two sets 
with significantly different OS (supplementary figure 2D).  
 
Novel grading algorithms based on discovery set 
Multivariate analysis including all parameters exhibiting a significant association with OS 
(table 1) was performed to develop grading models that could be compared with the current 
2016 CNS WHO standard. Three different models were generated. The first approach 
(Modelpath) aimed at minimizing the required molecular data input, which would presumably 
allow for the most widespread applicability. In addition to IDH and 1p/19q testing, the first 
approach only requires the determination of CDKN2A/B status. The second approach, 
ModelCNVL made use of all molecular data available. Because ModelCNVL in the discovery set 
placed a set of 7 patients with necrosis into the most favorable group, we created a 
Modelcombined, which shifted these patients to the patient group with intermediate OS (Figure 
2). While this model was not based on a mathematical procedure, it worked well in the 
discovery and all validation sets.  
Modelpath demonstrated that an algorithm based on employment of absence/presence of 
homozygous CDKN2A/B deletion and absence/presence of necrosis formed three groups 
among the 211 tumors in the discovery cohort. In this Modelpath, patients with homozygous 
deletion of CDKN2A/B exhibited the worst OS and were termed astrocytoma, IDH-mutant, 
grade 4, pathology (A4path). This group comprised 38 tumors of the discovery cohort and 
contained 23 GBMIDHmut and 15 AAIIIIDHm. Tumors with necrosis but without homozygous 
CDKN2A/B deletion fared significantly better and were termed astrocytoma, IDH-mutant, 
grade 3, pathology (A3path). A3path contained 44 tumors which by definition were all GBMIDHm. 
The remaining 129 patients with neither homozygous CDKN2A/B deletion nor necrosis were 
termed astrocytoma, IDH-mutant, grade 2, pathology (A2path). A2path contained 75 AAIIIIDHmut 
and 54 AIIIDHm. OS plots of the discovery set assembled according to 2016 CNS WHO and 
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according to Modelpath are shown (figure 3a and 3b). Modelpath performed better in predicting 
OS of the groups than the 2016 CNS WHO did as illustrated by Brier scores (figure 4a).  
ModelCNVL relied on absence/presence of homozygous CDKN2A/B deletion and on a 
threshold value of 350 Mb for CNVL. Therefore, A4 were determined as in our first approach. 
However, the remaining patients were subdivided with those having a CNV-L value < 350 Mb 
being termed astrocytoma, IDH-mutant, grade 2, CNVL (A2CNVL) and those with value > 350 
Mb being termed astrocytoma, IDH-mutant, grade 3, CNVL (A3CNVL). A2CNVL featured 86 
patients containing 7 GBMIDHmut, 42 AAIIIIDHmut and 37 AIIIDHm. A3CNVL contained 87 patients, 
with 37 GBMIDHmut, 33 AAIIIIDHmut and 17 AIIIDHm. A OS plot of the discovery set according to 
ModelCNVL is shown (figure 3c). ModelCNVL performed better in predicting OS of the groups 
than the 2016 CNS WHO did as illustrated by Brier scores (figure 4a). 
Modelcombined was devised to circumvent the provocative shift of patients with necrosis but 
without CDKN2A/B deletion and with a low CNVL into the most favorable patient group 
(figure 2). Instead, this patient group was placed in the intermediate malignancy group. 
Notably, Modelcombined is not based on a strict mathematical approach. The number of only 
seven patients in this group is too small to confirm OS comparable to that of patients in the 
intermediate malignancy group (supplementary figure 3). In Modelcombined the A4 group 
defined by homozygous CDKN2A/B deletion was identical to that in Modelpath and ModelCNVL. 
Modelcombined also performed better in predicting OS of the groups than the 2016 CNS WHO 
could accomplish as illustrated by Brier scores (figure 4a). 
Importantly, all three-tiered grading approaches, i.e. WHO, Modelpath, ModelCNVL and 
Modelcombined were predictive with higher power than two-tiered approaches based on 
unsupervised clustering and the classifier tool (figure 4a). 
 
Validation of the study series 
The validation sets supported our findings from the discovery set.  
In the HD validation set, WHO based separation was of borderline significance (p=0.05) 
(Figure 3e). In contrast, Modelpath or ModelCNVL both significantly separated three prognostic 
patient groups (p<0.0001) (figure 3f and g). Best performance was achieved by Modelcombined 
(Figure 3h).  
The EORTC validation set produced comparable results (figure 3i, j, k, and l). Here the 2016 
CNS WHO did separate groups with different OS (p=0.004). Modelpath performed slightly 
better (p=0.002), however, ModelCNVL and Modelcombined again provided best separation into 
groups of different OS (p< 0.0001).  
The TCGA dataset was only of limited value for validating our models due to a high number 
of cases with relatively short observation periods. We observed a good separation of patients 
recognized by our models as highly malignant due to presence of a homozygous CDKN2A/B 
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deletion. TCGA patients with CDKN2A/B homozygous deletion also died relatively quickly 
and therefore separated significantly from patients without such deletion. However, the 
separation between the intermediate and more favorable tumor groups was not possible due 
to a high number of patients lacking long-term follow up. Thus, due to its composition the 
TCGA validation set only could be used for validating the poor OS of patients with 
homozygous CDKN2A/B deletion (Figure 3m, n, o and p).  
In conclusion, in all three validation sets the tested grading models performed better than the 
current WHO system. 
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Discussion 
 
Using combined histological and genetic parameters, notably necrosis and CDKN2A/B 
deletion, we have established a novel grading system for IDH-mutant diffuse astrocytic 
tumors. Interestingly, this system does not incorporate morphological estimates of 
proliferation, which have been a key parameter in WHO grading systems through counting 
mitotic figures. Indeed, CDKN2A/B homozygous deletion is tightly linked to proliferation 
because loss of p16 removes the inhibition of complexes of CDK4 with D-type cyclins 
thereby driving the cell cycle. In our discovery set CDKN2A/B homozygous deletion was 
clearly associated with higher proliferation. However, a considerable fraction of patients 
lacking the deletion still exhibited high Ki-67 reads (supplementary figure 4). 
By focusing on this marker rather than quantifying proliferation, grading accuracy may 
improve because the difficulties underlying precise determination of mitotic counts (e.g., 
interobserver variations, tissue artifacts, interfering staining conditions, sampling, or 
extended time from tissue removal to fixation) are eliminated.  
In our discovery set, mitotic count was not a strong predictor of outcome. This confirms 
previous reports pointing to the failure of morphological proliferation assessment in predicting 
clinical outcome in IDH-mutant astrocytic gliomas [20,28]. Likewise, Ki67 staining 
ubiquitously used as a parameter for estimating proliferation provides variable readouts 
dependent on staining or processing conditions and, therefore, is problematic for the 
determination of cutoff values to discern malignancy grades. 
Proliferation assessed by Ki-67 is described as low or absent in AIIIDHmut in the 2016 CNS 
WHO 2016 [17]. In our discovery set, Ki-67 is significantly associated prognosis, but the split 
point was determined around 15%. A reason for the failure of Ki-67 as a prognostic 
parameter in WHO is the low split point (often near 2%) in the previous studies [11,15]. 
These studies all were from the pre-IDH era and contained many glioblastomas, thus driving 
the split points to low values. This may explain why the 2016 CNS WHO stated that Ki-67 
was not prognostic for AAIIIIDHmut [17]. 
The presence of homozygous CDKN2A/B deletion turned out to be the most powerful 
parameter for inferior clinical outcome. This parameter is currently not employed in WHO 
grading, but could be construed as a molecular estimate of proliferation given the role of the 
p16 protein in regulating the cell cycle. Interestingly, CDKN2A/B homozygous deletion in 
tumors without necrosis, graded AAIIIIDHmut, was associated with OS indistinguishable from 
that of patients with tumors exhibiting both CDKN2A/B homozygous deletion and necrosis 
that were diagnosed by definition as GBMIDHmut (figure 1b). And in turn, by removing tumors 
with CDKN2A/B homozygous deletion among AAIIIIDHmut, OS of the remaining patients did 
not significantly (p = 0.124) differ from that AIIIDHmut (figure 1b). CDKN2A/B homozygous 
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deletion or mutations in the RB pathway have been determined as an unfavorable parameter 
in previous studies [1,26]. We therefore performed an analysis combining cases with either 
CDKN2A/B homozygous deletion or RB1 homozygous deletion or CDK4 or CDK6 
amplification. However, this did not result in an overall improvement of separating groups of 
patients with different outcome in all tumor sets. We think this partly due to the more 
pronounced association of CDKN2A/B homozygous deletion with survival than that of the 
other RB1 pathway genes analyzed (supplementary figure 5) While combining typical lesions 
of the RB1 pathway should be further explored, we expect that mainly the assessment of 
CDKN2A/B status will be highly relevant for future diffuse astrocytoma grading systems. 
Satisfactory data acquisition can be performed by FISH, by quantitative PCR or by array 
technology as performed in this study. As shown elsewhere, CDKN2A/B status may be 
readily determined by FISH analysis [23,25]. Given the utility of immunohistochemistry for 
routine pathology diagnosis, we tried to detect homozygous deletion of the CDKN2A gene 
product p16 by immunohistochemistry. Unfortunately, using p16 antibody cloneG175-405 
(BD-Biosciences) we could not show satisfactory correlation between p16 
immunohistochemistry and molecular detection of CDKN2A homozygous deletion. In our 
immunohistochemistry, the basal nuclear expression of p16 was too low in many samples to 
allow definite detection of loss of expression. Our observation is supported by another study 
observing a correlation of p16 expression loss and CDKN2A deletion, however only in 85% 
of the deleted tumors [25]. We consider this correlation not tight enough and, therefore, favor 
determination of CDKN2A/B deletion by an assay addressing DNA directly. A representative 
CNP with evident CDKN2A/B homozygous deletion is shown in supplementary figure 6.  
Another key parameter, the presence of necrosis, which according to the 2016 CNS WHO 
results in the diagnosis of GBMIDHmut, appears overrated in terms of estimating prognosis in 
IDH-mutant diffuse astrocytomas. As a single factor, necrosis is prognostically highly 
significant in our discovery set (table1), but the presence of necrosis in the absence of 
homozygous CDKN2A/B deletion was associated with clearly better prognosis than that of 
tumors containing the homozygous deletion (figure 1b). To account for these observations, 
we developed grading models based on those parameters that turned out to predict clinical 
outcome better than grading according to the 2016 CNS WHO (figure 2). Better outcome 
prediction could be confirmed in two independent validation series and better detection of 
patients at risk for poor OS could be achieved in the TCGA set with shorter observation 
periods only (figure 3). Our data on the TCGA data are in line with a previous study on the 
TCGA LGG data set reporting that CDKN2A homozygous deletion, but not expression 
associates with unfavorable OS [29]. Because all three tiered grading approaches in this 
study predicted OS with less error than the two-tiered grading schemes emerging from 
unsupervised clustering or from using the methylation-based classifier [5], the latter were not 
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further considered, although both schemes proved stable in the validation series (figure 4a 
and b and supplementary figure 2a, b, c, d, e ,f and 5) 
An interesting parameter emerging from our analysis was CNVL. A proportion higher than 
350 Mb either lost or gained in the areas covered by the methylation arrays correlated with 
poorer OS. Previously, the mutational load has been shown to correlate with tumor grade in 
IDH-mutant glioma [9]. While our data more reflect genomic instability and those data rely on 
an accumulation of mutations they also support a quantitative approach to tumor grading.  
 
Shifts of patients according to different grading approaches 
WHO grading and our grading models result in three different groups, however with different 
distributions. The allotment of patients in the discovery set to Model-specific sets is provided 
in supplementary table 1. Our novel approaches lead to a higher overall number of diffuse 
astrocytomas in the lower-grade group. This effect is more pronounced for Modelpath than for 
ModelCNVL. In Modelpath, the increase from 54 AIIIDHmut to 129 A2path comes with the reduction 
of median OS from 7053 days to 5122 days. In contrast, the increase from 54 AIIIDHmut to 86 
A2CNVL did not alter the median OS of 7053 days. The shifts in patient numbers in the 
comparable groups is mainly due to the strong influence of proliferation rate on the WHO 
grading algorithm. The typical problem is exemplified by a well differentiated diffuse 
astrocytoma being currently diagnosed as a WHO grade III tumor because of the detection of 
a few mitotic figures. In such a setting, the clinician may be surprised by a grade III 
designation given the lack of neuroradiological or intraoperative evidence for higher grade. 
The novel grading approaches described here appear to address this clinicopathological 
problem. It should be noted that the diagnostic considerations underlying WHO grading of 
the discovery set already deviated from the traditional WHO guidelines due to the experience 
of the authors who diagnosed and graded the tumors [20,28] In particular, more than single 
mitoses were accepted as compatible with AIIIDHmut. In the setting of IDH mutations, the 
presence of few mitotic figures did not result in a diagnosis of AAIIIIDHmut. This may be 
another reason for “standard” grading successfully predicting OS in the discovery set. 
Our data demonstrate that AAIIIIDHmut stratified for CDKNA homozygous deletion separates 
into two groups with quite different OS: patients with tumors lacking this lesion follow a 
moderately aggressive course while patients with tumors having a CDKN2A/B deletion fare 
more similar to patients with GBMIDHmut with homozygous deletion but much worse than 
patients with GBMIDHmut lacking CDKN2A/B homozygous deletion (figure 1B). Thus 
combining patients with AIIIDHmut and AAIIIIDHmut but lacking homozygous deletion of 
CDKN2A/B into a single group in ModelPath forms a fairly homogenous cohort and may have 
implications for the nomenclature of these tumors as well as a potential therapeutic 
relevance. 
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ModelPath results in reduction of the size of the intermediate grading group. In the discovery 
set, AAIIIIDHmut with 90 patients constitutes the largest group. The equivalent group according 
to Modelpath includes 44 patients. This contrasts ModelCNVL which allots 87 patients to the 
intermediate group. The relation of the A3path and A3CNVL groups is analyzed in 
Modelcombined based on CDKN2A/B, necrosis and CNV-L (figure 3b, c and d). The power of 
this model is best exemplified by the lowest prediction error rate as shown by Brier score 
(figure 4a for discovery set, figure 4b for HD-validation set). 
 
Implication for the use of morphological parameters proliferation and necrosis 
Our data challenge the value of two main criteria that have long been used in the grading of 
diffuse astrocytomas: proliferation and necrosis. As previously reported [20], mitotic count is 
of less significance in a set of IDH-mutant diffuse astrocytomas than in a set of diffuse 
astrocytomas not tested for IDH status (and thereby likely to contain a substantial fraction of 
biological glioblastomas). In our analyses, mitotic figures did not emerge as a parameter 
providing the most significant separation of patients with IDH-mutant diffuse astrocytoma in 
groups with different OS. We therefore suggest a more conservative use of proliferation and 
caution to use this as a sole indicator for high tumor grade.  
The other grading parameter in question is necrosis. The presence of necrosis in a diffuse 
astrocytic neoplasm that had not been pretreated inevitably prompted the WHO diagnosis of 
GBMIDHmut. However, patients with tumors exhibiting necrosis but not containing homozygous 
CDKN2A/B deletion survive significantly better than patients with tumors lacking necrosis but 
containing a CDKN2A/B homozygous deletion (figure 1b). This observation in our discovery 
and validation series (figure 3) should prompt a more conditional approach to the presence of 
necrosis as a parameter for grading of higher-grade diffuse astrocytic tumors. 
 
Clinical perspective of grading according to the novel approaches 
Caveats of our study are the heterogeneity of treatment and the potential effect of treatment 
on OS. Patients with AAIIIIDHmut and AIIIDHmut.have been treated quite heterogeneously with 
therapies ranging from wait and see to radiotherapy, chemotherapy or combinations thereof. 
In general, patients with AAIIIIDHmut may have been likely to receive a more intense treatment 
than patients with AIIIDHmut .We cannot exclude the possibility of treatment being effective in 
patients with AAIIIIDHmut, thereby blurring the distinction to OS of patients with AIIIDHmut.. 
Nonetheless, the current treatment for AIIIDHmut and AAIIIIDHmut is similar in most centers. 
Therefore, the shift of patients between the corresponding groups following grading 
according to our novel approaches will likely not have an immediate effect on treatment. 
However, upon applying Modelcombined we subdivide AIIIDHmut into A2combined and A3combined. 
Patients with A2combined, although more numerous than those in AIIIDHmut, appear to exhibit a 
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slightly better OS than patients with AIIIDHmut. This may prompt future consideration regarding 
therapy in A2combined patients. In contrast, patients with A3combined show average OS closer to 
AAIIIIDHmut patients, thereby potentially supporting similar treatments for these groups. In turn, 
it will be of interest to determine if patients with GBMIDHmut should receive the same treatment 
as those patients with GBMIDHmut lacking homozygous CDKN2A/B deletion since these 
patients have OS approaching that of AAIIIIDHmut. Finally, patients assigned to the least 
favorable A4 group all exhibit homozygousCDKN2A/B deletion; such patients are in need of 
maximal treatment and could possibly benefit from treatment with CDK antagonists because 
CDKN2A/B deletion results in increased CDK activity [24]. 
 
Implications for the classification and grading of IDH-mutant diffuse astrocytic tumors 
The 2016 CNS WHO divided the traditionally termed “glioblastoma” into GBMIDHwt, GBMIDHmut 
and, in specific situations, diffuse midline glioma, H3K27–mutant. Genetically, these three 
groups are entirely different. While the diffuse midline glioma, H3K27–mutant is semantically 
clearly set apart from GBMIDHwt, the latter shares the same “family name” with GBMIDHmut [18]. 
However, there appears to be greater genetic kinship between GBMIDHmut and AIDHmut and not 
between GBMIDHmut and GBMIDHwt. This kinship is also supported by the distribution of other 
mutations such as ATRX or TP53 that are typically seen in these tumors and by the rarity of 
many mutations typical for GBMIDHwt such as EGFR amplification. Thus a genetic approach 
to taxonomy would favor a term such as “high-grade AIDHmut“ rather than the current term of 
GBMIDHmut. 
However, this still would be in conflict with a harmonious grading scale. Clearly, GBMIDHmut 
has a better prognosis than GBMIDHwt. In fact, GBMIDHmut has a better prognosis than the 
prognosis allotted to the pre-IDH era anaplastic astrocytoma WHO grade III (AAIIINOS) [34]. 
This circumstance would argue for a lower grade than currently allotted to the GBMIDHmut. 
However, the novel creation of an IDH-mutant glioblastoma grade 3 would seem 
awkward[18]. 
We suggest that future grading approaches include assessment of homozygous CDKN2A/B 
deletion in these tumors, given its powerful association with poorer prognosis. This accounts 
for both GBMIDHmut and AAIIIIDHmut – resulting in essential irrelevance of the presence of 
necrosis on OS in tumors with homozygous CDKN2A/B deletion. In other words, a definable 
fraction of AAIIIIDHmut fare significantly worse than a fraction of the GBMIDHmut. This cannot be 
repaired using the current WHO nomenclature without major changes to our historical 
concepts of nomenclature [18]. 
One possible solution, which we have considered implementing in Heidelberg, would be to 
restrict classification to the term AIDHmut and then adapt grading according to molecular 
lesions, thereby omitting the term GBMIDHmut. The term “glioblastoma” would be reserved for 
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those histologically defined glioblastomas lacking IDH mutation or not having had adequate 
(not otherwise specified, NOS) or diagnostic (not elsewhere classified, NEC) work-ups [19]. 
Such a system would lend itself well to the use of layered reports, as discussed elsewhere 
[16]. In this context, if these data were confirmed in other studies, the WHO classification of 
such tumors could resemble what is given in supplementary table 2 (based on Modelpath). 
Advantages of such an approach would include better prognostic correlations and therefore 
guidance of therapies, and a “freeing up” of grading from classification that could allow more 
easy adaptation of grading criteria in the future [18].  
 
Conclusions 
The 2016 CNS WHO grading of IDH-mutant astrocytic tumors is not as prognostically 
meaningful as needed and the histological parameters of proliferation and necrosis appear 
overrated when incorporating IDH gene status. Significantly, several other morphological and 
molecular parameters show higher prognostic power and modeling has provided suggestions 
for grading algorithms, with the proposal that CDNK2A/B status will be important for future 
grading of these tumors. 
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Figure legends 
 
Table 1 
Morphological and clinical features and their association with OS in the discovery set. 
 
 
Table 2 
Genes with amplifications or homozygous deletions found in 211 IDH-mutated astrocytomas 
in the discovery set and their association with OS. Univarate analysis. 
 
 
Figure 1 
Kaplan-Meier plot stratifying according to WHO in the discovery set (a). (b) shows the same 
patients with additional stratification for homozygous deletion of CDKN2A/B. 
 
 
Figure 2 
Distribution of 211 patients in the discovery set according to WHO grading and to three 
different grading approaches. N+ ~ necrosis present; N- ~ necrosis absent; P+ ~ CDKN2A/B 
is homozygously deleted; P- ~ CDKN2A/B is not homozygously deleted; C+ ~ high CNVL-
load; C- ~ low CNVL-load. Parameter P+ is not encountered in AIIIDHmut and, therefore, this 
potential tumor subset is not depicted in the three alternative grading approaches. 
Top: Grading model applied. Middle: Placement of patient groups with distinct features 
according to the four different approaches. Bottom: OS of patients according to the four 
approaches. 
 
 
Figure 3 
Kaplan-Meier plots stratifying according to WHO, Modelpath and ModelCNVL and Modelcombined 
in the discovery set (a, b, c, d), the HD validation set (e, f, g, h) the EORTC validation set (i, j, 
k, l) and the TCGA set (m, n, o, p).  
Coulor schemes for WHO: red GBMIDHmut, blue AAIIIIDHmut, green AIIIDHmut; for Modelpath: red 
A4, blue A3path, green A2path; for ModelCNVL: red A4, blue A3CNVL, green A2CNVL; for 
Modelcombined: red A4, blue A3combined, green A2comined.  
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Figure 4 
Brier scores to the grading approaches in the discovery set (a) and HD-validation set (b): 
reference which was random distribution (black), classifier tool (orange) based on 
epigenomic classification[5], unsupervised clustering of 850K based methylation data 
(yellow), WHO diagnosis (red), Modelpath (blue), ModelCNVL (green) and Modelcombined (purple.) 
 
 
Supplementary table 1 
Discovery set data employed in grading schemes for IDH-mutant astrocytoma. For each 
scheme lowest grade is indicated by green, intermediate grade by blue and highest grade by 
red color. 
 
Supplementary Table 2 
Possible designation of IDH-mutant astrocytoma based on Modelpath in a future classification 
scheme 
 
 
Supplementary figure 1 
Copy number summary plots. Vertical axis indicates percentage of patients affected. 
Horizontal axis refers to chromosomal localization. Dotted vertical lines indicate border 
between p and q arms. Data are given for three age groups. 
 
 
Supplementary figure 2 
Kaplan-Meier plots stratifying by unsupervised clustering in the discovery set (a), the HD 
validation set (b) and the EORTC validation set (c). 
Kaplan-Meier plots stratifying by the methylation based classifier in the discovery set (d), the 
HD validation set (e) and the EORTC validation set (f). 
 
 
Supplementary figure 3 
OS of subgroups in Modelcombined. The patient set (n = 7) characterized by necrosis, absence 
of CDKN2A/B homozygous deletion and low CNVL exhibited only 2 events. While the 
corresponding curve (red) fits well the group of patients with intermediate OS, the number is 
too low for a clear statement. 
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Supplementary figure 4 
Association of proliferation markers with CDKN2A/B status. (a) association with Ki67. (b) 
association with pHH3. Horizontal bars in box-plots correspond to median values. 
 
 
Supplementary figure 5 
OS of patients with IDH-mutant astrocytoma in association with RB pathway genes. (a) red -
homozygous deletion of CDKN2A/B, black – wild type status. (b) red –homozygous deletion 
of RB1 or CDK4 amplification or CDK6 amplification, black – wild type status. . (a) red -
homozygous deletion of CDKN2A/B or homozygous deletion of RB1 or CDK4 amplification or 
CDK6 amplification, black – wild type status for all. 
 
 
Supplementary figure 6 
Examples for CNP from astrocytic tumors exhibiting homozygous deletion of CDKN2A/B. 
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case Age gender WHO OS CDKN2A/B Necrosis CNVL (bp) Modelpath ModelCNVL Modelcombined 
1 37 f AIIIDHmut 4022 balanced no 276499911 A2path A2CNVL A2combined 
2 51 f AIIIDHmut 3275 balanced no 275244442 A2path A2CNVL A2combined 
3 26 m AIIIDHmut 7053 hetdel no 118472068 A2path A2CNVL A2combined 
4 28 f AIIIDHmut 6497 balanced no 100902350 A2path A2CNVL A2combined 
5 24 m AIIIDHmut 5122 hetdel no 12386106 A2path A2CNVL A2combined 
6 23 f AIIIDHmut 1731 balanced no 274819415 A2path A2CNVL A2combined 
7 54 f AIIIDHmut 2700 hetdel no 32231326 A2path A2CNVL A2combined 
8 29 m AIIIDHmut 448 balanced no 54866147 A2path A2CNVL A2combined 
9 38 f AIIIDHmut 2314 balanced no 228565769 A2path A2CNVL A2combined 
10 46 m AIIIDHmut 1481 balanced no 304920289 A2path A2CNVL A2combined 
11 25 m AIIIDHmut 4207 balanced no 120631604 A2path A2CNVL A2combined 
12 29 f AIIIDHmut 2190 balanced no 305279829 A2path A2CNVL A2combined 
13 38 f AIIIDHmut 1917 balanced no 147031947 A2path A2CNVL A2combined 
14 43 m AIIIDHmut 2852 hetdel no 214674094 A2path A2CNVL A2combined 
15 26 f AIIIDHmut 129 balanced no 73687679 A2path A2CNVL A2combined 
16 31 f AIIIDHmut 3310 balanced no 166849942 A2path A2CNVL A2combined 
17 31 f AIIIDHmut 4769 balanced no 157179197 A2path A2CNVL A2combined 
18 50 f AIIIDHmut 6896 balanced no 306090692 A2path A2CNVL A2combined 
19 25 f AIIIDHmut 2769 balanced no 87857691 A2path A2CNVL A2combined 
20 36 m AIIIDHmut 3110 balanced no 134873237 A2path A2CNVL A2combined 
21 43 m AIIIDHmut 5151 balanced no 296069657 A2path A2CNVL A2combined 
22 32 m AIIIDHmut 4947 balanced no 318517227 A2path A2CNVL A2combined 
23 46 m AIIIDHmut 4083 hetdel no 211988482 A2path A2CNVL A2combined 
24 28 f AIIIDHmut 2877 balanced no 63527897 A2path A2CNVL A2combined 
25 25 m AIIIDHmut 968 balanced no 90983369 A2path A2CNVL A2combined 
26 28 m AIIIDHmut 2980 hetdel no 272577994 A2path A2CNVL A2combined 
27 28 f AIIIDHmut 3624 balanced no 97759160 A2path A2CNVL A2combined 
28 26 m AIIIDHmut 6411 balanced no 42297630 A2path A2CNVL A2combined 
29 34 f AIIIDHmut 7574 balanced no 80568258 A2path A2CNVL A2combined 
30 35 f AIIIDHmut 2270 balanced no 201135535 A2path A2CNVL A2combined 
31 26 m AIIIDHmut 6549 balanced no 1875847 A2path A2CNVL A2combined 
32 52 f AIIIDHmut 1849 balanced no 208322963 A2path A2CNVL A2combined 
33 36 m AIIIDHmut 2074 hetdel no 298249331 A2path A2CNVL A2combined 
34 39 f AIIIDHmut 21 balanced no 40784782 A2path A2CNVL A2combined 
35 31 m AIIIDHmut 100 hetdel no 234203374 A2path A2CNVL A2combined 
36 31 m AIIIDHmut 2182 hetdel no 246267203 A2path A2CNVL A2combined 
37 29 m AIIIDHmut 2297 balanced no 97150870 A2path A2CNVL A2combined 
38 38 f AIIIDHmut 2342 balanced no 633608335 A2path A3CNVL A3combined 
39 32 m AIIIDHmut 2556 balanced no 442770300 A2path A3CNVL A3combined 
40 28 f AIIIDHmut 6394 gain no 440940501 A2path A3CNVL A3combined 
41 30 f AIIIDHmut 4302 hetdel no 763615945 A2path A3CNVL A3combined 
42 37 m AIIIDHmut 1693 balanced no 358458133 A2path A3CNVL A3combined 
43 46 f AIIIDHmut 1104 balanced no 426876972 A2path A3CNVL A3combined 
44 29 m AIIIDHmut 2491 balanced no 430413652 A2path A3CNVL A3combined 
45 51 m AIIIDHmut 2901 hetdel no 526514536 A2path A3CNVL A3combined 
46 70 f AIIIDHmut 709 balanced no 377719470 A2path A3CNVL A3combined 
47 46 m AIIIDHmut 3058 balanced no 403543802 A2path A3CNVL A3combined 
48 67 f AIIIDHmut 2672 hetdel no 836373426 A2path A3CNVL A3combined 
49 51 f AIIIDHmut 2219 hetdel no 646859920 A2path A3CNVL A3combined 
50 29 m AIIIDHmut 2278 balanced no 484645537 A2path A3CNVL A3combined 
51 41 m AIIIDHmut 5971 hetdel no 704332454 A2path A3CNVL A3combined 
52 41 m AIIIDHmut 228 balanced no 662264513 A2path A3CNVL A3combined 
53 67 f AIIIDHmut 1173 balanced no 572896836 A2path A3CNVL A3combined 
54 34 m AIIIDHmut 379 balanced no 406233411 A2path A3CNVL A3combined 
55 35 f AAIIIIDHmut 363 hetdel no 178096653 A2path A2CNVL A2combined 
56 22 m AAIIIIDHmut 3641 hetdel no 197533690 A2path A2CNVL A2combined 
57 26 m AAIIIIDHmut 6081 hetdel no 103568330 A2path A2CNVL A2combined 
58 35 m AAIIIIDHmut 2598 balanced no 200733683 A2path A2CNVL A2combined 
59 42 f AAIIIIDHmut 2661 balanced no 132505213 A2path A2CNVL A2combined 
60 32 m AAIIIIDHmut 664 balanced no 104349865 A2path A2CNVL A2combined 
61 32 f AAIIIIDHmut 422 hetdel no 187991641 A2path A2CNVL A2combined 
62 37 f AAIIIIDHmut 1758 gain no 304204478 A2path A2CNVL A2combined 
63 42 f AAIIIIDHmut 1219 gain no 187801981 A2path A2CNVL A2combined 
64 26 m AAIIIIDHmut 1691 balanced no 145503063 A2path A2CNVL A2combined 
65 25 m AAIIIIDHmut 1488 balanced no 207787601 A2path A2CNVL A2combined 
66 31 f AAIIIIDHmut 1033 hetdel no 315520776 A2path A2CNVL A2combined 
67 35 m AAIIIIDHmut 1444 balanced no 255473408 A2path A2CNVL A2combined 
68 25 f AAIIIIDHmut 41 balanced no 283494206 A2path A2CNVL A2combined 
69 36 m AAIIIIDHmut 146 balanced no 42705800 A2path A2CNVL A2combined 
70 55 m AAIIIIDHmut 546 balanced no 6385695 A2path A2CNVL A2combined 
71 35 f AAIIIIDHmut 961 balanced no 245265283 A2path A2CNVL A2combined 
72 35 m AAIIIIDHmut 1371 balanced no 194100168 A2path A2CNVL A2combined 
73 42 f AAIIIIDHmut 1892 balanced no 169361691 A2path A2CNVL A2combined 
74 37 f AAIIIIDHmut 1772 balanced no 107496655 A2path A2CNVL A2combined 
75 37 m AAIIIIDHmut 1289 balanced no 173539970 A2path A2CNVL A2combined 
76 31 m AAIIIIDHmut 3089 balanced no 88952640 A2path A2CNVL A2combined 
77 36 f AAIIIIDHmut 2911 balanced no 143626885 A2path A2CNVL A2combined 
78 37 m AAIIIIDHmut 2843 balanced no 178612373 A2path A2CNVL A2combined 
79 30 m AAIIIIDHmut 4194 balanced no 337431093 A2path A2CNVL A2combined 
80 36 m AAIIIIDHmut 3583 balanced no 77900000 A2path A2CNVL A2combined 
81 61 m AAIIIIDHmut 586 balanced no 209203001 A2path A2CNVL A2combined 
82 20 f AAIIIIDHmut 2621 balanced no 76220792 A2path A2CNVL A2combined 
83 32 m AAIIIIDHmut 5716 balanced no 196477555 A2path A2CNVL A2combined 
84 36 m AAIIIIDHmut 2234 balanced no 120190000 A2path A2CNVL A2combined 
85 31 m AAIIIIDHmut 1876 balanced no 64692119 A2path A2CNVL A2combined 
86 35 m AAIIIIDHmut 808 hetdel no 47784811 A2path A2CNVL A2combined 
87 18 f AAIIIIDHmut 2527 balanced no 165846610 A2path A2CNVL A2combined 
88 20 m AAIIIIDHmut 552 balanced no 17370000 A2path A2CNVL A2combined 
89 41 m AAIIIIDHmut 541 balanced no 193578368 A2path A2CNVL A2combined 
90 60 m AAIIIIDHmut 1116 balanced no 206039846 A2path A2CNVL A2combined 
91 34 m AAIIIIDHmut 1112 balanced no 138650339 A2path A2CNVL A2combined 
92 32 f AAIIIIDHmut 189 balanced no 249098921 A2path A2CNVL A2combined 
93 34 m AAIIIIDHmut 4403 balanced no 349695798 A2path A2CNVL A2combined 
94 31 m AAIIIIDHmut 8152 hetdel no 84825223 A2path A2CNVL A2combined 
95 27 f AAIIIIDHmut 2351 balanced no 1852897 A2path A2CNVL A2combined 
96 27 m AAIIIIDHmut 86 balanced no 100983650 A2path A2CNVL A2combined 
97 39 f AAIIIIDHmut 2049 balanced no 498665062 A2path A3CNVL A3combined 
98 56 m AAIIIIDHmut 253 hetdel no 636279064 A2path A3CNVL A3combined 
99 44 f AAIIIIDHmut 5464 balanced no 760800250 A2path A3CNVL A3combined 
100 45 f AAIIIIDHmut 1581 balanced no 423820854 A2path A3CNVL A3combined 
101 32 f AAIIIIDHmut 1145 hetdel no 453251583 A2path A3CNVL A3combined 
102 38 m AAIIIIDHmut 622 balanced no 689926530 A2path A3CNVL A3combined 
103 46 f AAIIIIDHmut 793 hetdel no 434218283 A2path A3CNVL A3combined 
104 49 m AAIIIIDHmut 748 hetdel no 365496202 A2path A3CNVL A3combined 
105 53 m AAIIIIDHmut 269 balanced no 728398267 A2path A3CNVL A3combined 
106 30 m AAIIIIDHmut 2436 balanced no 363383060 A2path A3CNVL A3combined 
107 36 m AAIIIIDHmut 289 hetdel no 380840728 A2path A3CNVL A3combined 
108 48 f AAIIIIDHmut 1349 balanced no 510647250 A2path A3CNVL A3combined 
109 30 m AAIIIIDHmut 1754 balanced no 499800655 A2path A3CNVL A3combined 
110 33 m AAIIIIDHmut 476 balanced no 440645896 A2path A3CNVL A3combined 
111 50 f AAIIIIDHmut 2817 balanced no 358770474 A2path A3CNVL A3combined 
112 36 f AAIIIIDHmut 7 gain no 517861229 A2path A3CNVL A3combined 
113 48 f AAIIIIDHmut 1898 hetdel no 758714830 A2path A3CNVL A3combined 
114 33 m AAIIIIDHmut 2436 balanced no 468801667 A2path A3CNVL A3combined 
115 25 m AAIIIIDHmut 3467 balanced no 624356552 A2path A3CNVL A3combined 
116 30 f AAIIIIDHmut 186 balanced no 352744994 A2path A3CNVL A3combined 
117 36 m AAIIIIDHmut 1830 balanced no 618297540 A2path A3CNVL A3combined 
118 52 m AAIIIIDHmut 849 hetdel no 639333382 A2path A3CNVL A3combined 
119 53 m AAIIIIDHmut 3625 balanced no 1062531615 A2path A3CNVL A3combined 
120 46 m AAIIIIDHmut 2863 hetdel no 454173599 A2path A3CNVL A3combined 
121 46 m AAIIIIDHmut 2183 hetdel no 1315154012 A2path A3CNVL A3combined 
122 44 f AAIIIIDHmut 961 balanced no 673356226 A2path A3CNVL A3combined 
123 
 
m AAIIIIDHmut 2304 balanced no 484685201 A2path A3CNVL A3combined 
124 41 f AAIIIIDHmut 1442 balanced no 911535916 A2path A3CNVL A3combined 
125 30 m AAIIIIDHmut 1589 balanced no 1190727105 A2path A3CNVL A3combined 
126 58 m AAIIIIDHmut 1804 hetdel no 900853650 A2path A3CNVL A3combined 
127 46 m AAIIIIDHmut 61 balanced no 474539606 A2path A3CNVL A3combined 
128 37 m AAIIIIDHmut 4598 hetdel no 552397505 A2path A3CNVL A3combined 
129 66 f AAIIIIDHmut 787 balanced no 1069350769 A2path A3CNVL A3combined 
130 37 f AAIIIIDHmut 363 homodel no 465715427 A4 A4 A4 
131 36 f AAIIIIDHmut 1024 homodel no 831929597 A4 A4 A4 
132 55 m AAIIIIDHmut 581 homodel no 930444025 A4 A4 A4 
133 27 m AAIIIIDHmut 2315 homodel no 223793927 A4 A4 A4 
134 28 m AAIIIIDHmut 535 homodel no 296028886 A4 A4 A4 
135 68 m AAIIIIDHmut 1198 homodel no 866989174 A4 A4 A4 
136 56 m AAIIIIDHmut 879 homodel no 1312842881 A4 A4 A4 
137 40 m AAIIIIDHmut 677 homodel no 989539476 A4 A4 A4 
138 49 f AAIIIIDHmut 360 homodel no 1142771330 A4 A4 A4 
139 31 m AAIIIIDHmut 1680 homodel no 684135301 A4 A4 A4 
140 57 m AAIIIIDHmut 2184 homodel no 644588335 A4 A4 A4 
141 42 m AAIIIIDHmut 985 homodel no 1137070451 A4 A4 A4 
142 58 m AAIIIIDHmut 499 homodel no 1304553626 A4 A4 A4 
143 
 
m AAIIIIDHmut 1936 homodel no 222558442 A4 A4 A4 
144 25 f AAIIIIDHmut 880 homodel no 482618213 A4 A4 A4 
145 36 m GBMIDHmut 302 balanced present 0 A3path A2CNVL A3combined 
146 38 m GBMIDHmut 1293 hetdel present 193419378 A3path A2CNVL A3combined 
147 50 m GBMIDHmut 1070 hetdel present 347889943 A3path A2CNVL A3combined 
148 47 m GBMIDHmut 1063 balanced present 201362719 A3path A2CNVL A3combined 
149 33 m GBMIDHmut 1740 hetdel present 274299199 A3path A2CNVL A3combined 
150 34 m GBMIDHmut 3732 balanced present 324522740 A3path A2CNVL A3combined 
151 45 f GBMIDHmut 3102 balanced present 330020454 A3path A2CNVL A3combined 
152 15 m GBMIDHmut 1309 hetdel present 458136707 A3path A3CNVL A3combined 
153 41 m GBMIDHmut 1890 balanced present 1115095398 A3path A3CNVL A3combined 
154 38 m GBMIDHmut 1513 balanced present 545004153 A3path A3CNVL A3combined 
155 45 f GBMIDHmut 405 hetdel present 1590206155 A3path A3CNVL A3combined 
156 43 m GBMIDHmut 626 balanced present 618971955 A3path A3CNVL A3combined 
157 33 f GBMIDHmut 1505 hetdel present 941539384 A3path A3CNVL A3combined 
158 
 
m GBMIDHmut 1313 hetdel present 478025436 A3path A3CNVL A3combined 
159 27 m GBMIDHmut 765 balanced present 414171054 A3path A3CNVL A3combined 
160 35 f GBMIDHmut 665 balanced present 2059818464 A3path A3CNVL A3combined 
161 37 f GBMIDHmut 174 hetdel present 358097638 A3path A3CNVL A3combined 
162 44 f GBMIDHmut 917 hetdel present 593099167 A3path A3CNVL A3combined 
163 53 m GBMIDHmut 3544 balanced present 1136518981 A3path A3CNVL A3combined 
164 38 m GBMIDHmut 690 hetdel present 549311866 A3path A3CNVL A3combined 
165 23 m GBMIDHmut 480 balanced present 569558376 A3path A3CNVL A3combined 
166 51 m GBMIDHmut 330 hetdel present 903932607 A3path A3CNVL A3combined 
167 33 m GBMIDHmut 1710 balanced present 485848840 A3path A3CNVL A3combined 
168 38 f GBMIDHmut 3540 balanced present 707394101 A3path A3CNVL A3combined 
169 33 f GBMIDHmut 1860 hetdel present 570848619 A3path A3CNVL A3combined 
170 35 m GBMIDHmut 390 hetdel present 643888537 A3path A3CNVL A3combined 
171 23 m GBMIDHmut 1620 balanced present 451313723 A3path A3CNVL A3combined 
172 47 f GBMIDHmut 1740 balanced present 407272041 A3path A3CNVL A3combined 
173 41 m GBMIDHmut 1830 balanced present 369144405 A3path A3CNVL A3combined 
174 49 m GBMIDHmut 1020 balanced present 900834346 A3path A3CNVL A3combined 
175 
 
m GBMIDHmut 360 balanced present 1054050774 A3path A3CNVL A3combined 
176 26 m GBMIDHmut 1920 hetdel present 471542557 A3path A3CNVL A3combined 
177 25 m GBMIDHmut 2940 balanced present 511679183 A3path A3CNVL A3combined 
178 47 f GBMIDHmut 750 balanced present 781997801 A3path A3CNVL A3combined 
179 43 f GBMIDHmut 360 balanced present 1185670713 A3path A3CNVL A3combined 
180 31 f GBMIDHmut 1800 hetdel present 455864908 A3path A3CNVL A3combined 
181 37 f GBMIDHmut 2040 balanced present 555554816 A3path A3CNVL A3combined 
182 18 m GBMIDHmut 630 balanced present 572076605 A3path A3CNVL A3combined 
183 32 m GBMIDHmut 632 balanced present 422428971 A3path A3CNVL A3combined 
184 22 m GBMIDHmut 934 balanced present 766615685 A3path A3CNVL A3combined 
185 27 f GBMIDHmut 1582 balanced present 828095041 A3path A3CNVL A3combined 
186 38 m GBMIDHmut 360 balanced present 1544228140 A3path A3CNVL A3combined 
187 21 f GBMIDHmut 2413 balanced present 425183946 A3path A3CNVL A3combined 
188 31 m GBMIDHmut 734 hetdel present 847090386 A3path A3CNVL A3combined 
189 60 m GBMIDHmut 297 homodel present 807768413 A4 A4 A4 
190 41 m GBMIDHmut 1107 homodel present 495740703 A4 A4 A4 
191 32 m GBMIDHmut 676 homodel present 378012012 A4 A4 A4 
192 45 f GBMIDHmut 559 homodel present 659510395 A4 A4 A4 
193 38 m GBMIDHmut 763 homodel present 421896525 A4 A4 A4 
194 30 f GBMIDHmut 612 homodel present 774198635 A4 A4 A4 
195 52 m GBMIDHmut 744 homodel present 1007202573 A4 A4 A4 
196 52 m GBMIDHmut 355 homodel present 432740127 A4 A4 A4 
197 47 m GBMIDHmut 420 homodel present 354295141 A4 A4 A4 
198 37 m GBMIDHmut 1740 homodel present 673228823 A4 A4 A4 
199 32 m GBMIDHmut 1440 homodel present 713800664 A4 A4 A4 
200 30 f GBMIDHmut 1860 homodel present 409762641 A4 A4 A4 
201 42 f GBMIDHmut 510 homodel present 558904598 A4 A4 A4 
202 
 
f GBMIDHmut 1110 homodel present 1026408664 A4 A4 A4 
203 32 m GBMIDHmut 1020 homodel present 428821854 A4 A4 A4 
204 33 m GBMIDHmut 630 homodel present 889020134 A4 A4 A4 
205 29 f GBMIDHmut 360 homodel present 313871779 A4 A4 A4 
206 48 m GBMIDHmut 840 homodel present 2420702864 A4 A4 A4 
207 28 f GBMIDHmut 660 homodel present 616412044 A4 A4 A4 
208 32 m GBMIDHmut 1080 homodel present 265982563 A4 A4 A4 
209 27 m GBMIDHmut 13 homodel present 873352072 A4 A4 A4 
210 25 m GBMIDHmut 388 homodel present 960004694 A4 A4 A4 
211 56 m GBMIDHmut 1605 homodel present 919954069 A4 A4 A4 
 
 
Table 3 
 
 
Diffuse astrocytic tumours 
 
Diffuse astrocytic glioma, IDH-mutant, CDKN2A/B-intact, WHO grade II 
Diffuse astrocytic glioma, IDH-mutant, CDKN2A/B-intact with necrosis, WHO grade III 
Diffuse astrocytic glioma, IDH-mutant, CDKN2A/B-deleted, WHO grade IV 
 
Table 1 
 
 
parameter min max split n rate p-value 
age (years) 15 70 54 190 < 54; 92% < 0.05 
gender male 0 1 na 130 m; 62% 0.01 
cell count (n/mm2) 734 9143 4604 130 < 4604; 62% < 0.002 
Ki67 (%) 0 97 14.5 144 < 14.5; 71% < 0.01 
pHH3 count (n/10HPF) 0 327 no split 
   microvessel density (%) 0,2 8,7 1.2 82 >1.2; 39% < 0.05 
necrosis absent 0 1 na 144 present; 32% <0.000005 
vascular proliferation absent 0 1 na 129 absent; 61% <0.001 
 
Table 2 
 
 
gene alteration n p-value 
CCND1 amplification (cutoff 0.35) 1 0.17 
CCND2 amplification (cutoff 0.35) 27 0.15 
CDK4 amplification (cutoff 0.35) 18 0.11 
CDK6 amplification (cutoff 0.35) 6 0.13 
CDKN2A/B homo del (cutoff -0.415) 38 0.0001 
EGFR amplification (cutoff 0.35) 4 0.38 
MDM4 amplification (cutoff 0.35) 5 0.09 
MET amplification (cutoff 0.35) 11 0.39 
MYC amplification (cutoff 0.35) 13 0.89 
MYCN amplification (cutoff 0.35) 12 0.001 
NF1 homo del (cutoff -0.415) 4 0.52 
NF2 homo del (cutoff -0.415) 4 0.32 
PDGFRA amplification (cutoff 0.35) 13 0.03 
PPM1D amplification (cutoff 0.35) 1 0.70 
PTEN homo del (cutoff -0.415) 3 0.11 
RB1 homo del (cutoff -0.415) 12 0.001 
SMARCB1 homo del (cutoff -0.415) 2 0.26 
 
homo del = homozygous deletion 
 
